PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancer

PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancer - PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004389

Enrollment

Registered

2010-10-18

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent gastric cancer refractory to standard therapeutic modality

Interventions

Peptide vaccine therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance Status 0-1 Refractory to standard therapy

Exclusion criteria

Exclusion criteria: Pregnancy Uncontrolled infection Patients with serious concomitant disease

Design outcomes

Primary

Measure	Time frame
Safety Overall survival	—

Secondary

Measure	Time frame
Time to treatment failure Progression free survival Antitumor immune responses	—

Countries

Japan

Contacts

Public ContactFujiwara Yoshiyuki

Graduate School of Medicine,Osaka University Department of Gastroenterological Surgery

yfujiwara@gesurg.med.osaka-u.ac.jp06-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026